The vaccine has reduced cervical cancer by nearly 90% in women vaccinated as teens and has been studied in more than 50 randomized controlled trials.
Of all women, 20% preferred home-based self-sampling, while 61% preferred clinic-based testing, and 19% were unsure.
An observational study from China finds that menstrual blood can be used to screen for human papillomavirus which causes 90% of all cervical cancer.
Offering self-collection to all women can improve health equity and speed the global elimination of cervical cancer, the authors say.
The incidence of cervical lesions was 50% lower in unvaccinated women when vaccination was widespread.
For the first time, the federal government has issued cervical cancer screening recommendations that include an option for home testing.
For those vaccinated against HPV before age 17, their rate of vaginal or vulvar precancers was 57% lower than for unvaccinated women.
The vaccine was 97% effective, and protection did not wane during the follow-up period.
The analysis draws on data from more than 132 million people.
Researchers say reliance on earmarked voluntary contributions from external donors like the Gates Foundation undermines the WHO's independence.
